The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.
Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
Most head and neck cancer patients saw a decline in oral HPV DNA after treatment, but those who did not were more likely to experience disease recurrence.
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.
Gene expression data revealed two groups of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomas corresponding to distinct survival outcomes.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.
With integrated data for thousands of TCGA tumors, teams explored cancer subtypes, searched for prognostic insights, began mapping immune cell interactions, and more.
DCell, a visible neural network, uses deep learning techniques to model cellular behavior almost as accurately as has been observed in laboratory settings.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
